Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research-based pharmaceutical firm Sepracor has launched its insomnia treatment Lunesta, making the product available by prescription in most pharmacies across the US.
Subscribe to our email newsletter
Lunesta (eszopiclone) is the first and only sleep aid (prescription or over-the-counter), which has been approved by the FDA for long-term treatment of insomnia. It is also the first treatment in its class that has been shown to not only help patients fall asleep quickly, but also sleep all through the night.
Lunesta is approved as a prescription, non-narcotic sleep aid to treat insomnia. It has been studied in patients for up to 12 months and in over 30 clinical trials enrolling more than 4,700 patients.
“I am extremely pleased that millions of patients who have trouble sleeping, whether it be on a short- or long-term basis, have an effective new prescription treatment option available in their local pharmacy,” said Dr John Winkelman, associate director for the sleep disorders program at Brigham and Women’s Hospital, Boston.
“I expect that Lunesta, with its approval for long-term use and effectiveness in helping people stay asleep through the night, will allow most people who suffer from insomnia to get a refreshing night of sleep without feeling groggy the next day,” he continued.